Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Study of quadruple combination for induction resistant myeloma reveals novel immune checkpoints

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.12.19
Views: 308

Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Dr Yael Cohen speaks to ecancer at the ASH 2019 meeting in Orlando about results from the KyDaR trial,

She explains that the multi-centre trial uses the quadruple combination of carfilzomib, lenalidomide, dexamethasone and daratumumab (KRD-D) for induction resistant myeloma, along with conducting translational single-cell analysis.

Dr Cohen reports that not only did the patients show deep and sustained responses to the combination, but the trial also identified potential drivers of advanced resistance, including novel immune checkpoints.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation